Follow these directions for how to get rid of a stye and heal faster, courtesy of four eye health experts—plus, when to see a doctor.

A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...

A high-stakes legal fight between Regeneron and Amgen over the blockbuster eye drug Eylea is putting the U.S. patent system ...

Yesafili, a biosimilar to Eylea, received Health Canada's approval, marking the first such approval in Canada. Indicated for neovascular AMD, diabetic macular edema, and other ocular conditions, ...

European Commission approves Eylea 8 mg with extended 6-month treatment interval for nAMD and visual impairment due to DME ...

European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept)REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ...

Alvotech and Advanz Pharma announce positive EMA opinion for AVT06, a biosimilar to Eylea®, advancing access for eye disorder treatments in Europe.

AVT06 is a recombinant fusion protein and a biosimilar candidate to Eylea® (aflibercept), which binds vascular endothelial growth factors (VEGF), inhibiting the binding and activation of VEGF ...

Biotech seeks to stop Kirkland from representing rival in Eylea dispute Regeneron files motion to disqualify firm from patent and antitrust dispute | Motion cites conflict of interest due to ...